INMD - InMode rises as results expected to exceed consensus
- InMode ( NASDAQ: INMD ) rose ~6% pre-market as the medical technologies company said its Q4 revenue will be in the range of $133.2M to $133.4M, and FY22 revenue between $453.9M and $454.1M.
- The Q4 consensus revenue estimate is $129.45M and FY22 consensus stands at $448.71M.
- Q4 EPS is expected to be in the range of $0.73-$0.74, vs. consensus of $0.65, and FY22 EPS between $2.38 and $2.39, vs. consensus of $2.30.
- Non-GAAP gross margin is expected to be in the range of 83% to 85%.
- FY23 revenue will be in the range of $525M to $530M, vs. consensus of $522.75M.
- INMD is set to release its financial results for Q4 and FY22 before market opens on Feb. 14.
- Source: Press Release
For further details see:
InMode rises as results expected to exceed consensus